NCT06712121

Venetoclax and Decitabine in R/R T-ALL

A Phase 2 Clinical Trial to Evaluate the Efficacy of VEnetoclax and DEciTabine in Relapsed/Refractory Adult T-acute Lymphoblastic lEukemia/Lymphoma

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 28 (estimated)
• Sponsor: Seoul National University Hospital · Academic / Other
• Sex: All
• Age: 19 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The goal of this phase 2 clinical trial is to test the efficacy of decitabine and venetoclax combination chemotherapy in relapsed or refractory adult T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma. This study use a modified regimen of decitabine and venetoclax.

Detailed description

Our study is conducted in collaboration with Korean adult acute lymphoblastic leukemia working party (KALLWP) and consortium for improving survival of lymphoma (CISL). This study recruits adult patients with R/R T-ALL/LBL and treated with 7-day decitabine plus 3 weeks of venetoclax up to 12 cycles.

Conditions

• T Lymphoblastic Leukemia/Lymphoma

Interventions

Type	Name	Description
DRUG	decitabine plus venetoclax	decitabine 20mg/m2 for 7 days venetoclax 400mg daily for 21 days

Timeline

• Start date: 2025-01-30
• Primary completion: 2027-08-31
• Completion: 2028-08-31
• First posted: 2024-12-02
• Last updated: 2026-02-02

Locations

3 sites across 1 country: South Korea

Regulatory

• FDA-regulated drug study